Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CiplaLUX:CIPLA 97 EV-to-EBITDA is 21.23 as of Jul. 27, 2026, which is 35% above its 10-year median of 15.78. GuruFocus rates LUX:CIPLA with a GF Score™ of 97/100 and a GF Value™ of $19.91. The stock has 3 warning signs investors should review. Among 742 Drug Manufacturers companies, Cipla ranks worse than 64.29% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Cipla's enterprise value is $13,656 Mil.
Cipla's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was $643 Mil. Therefore, Cipla's EV-to-EBITDA for today is 21.23.
The historical rank and industry rank for Cipla's EV-to-EBITDA or its related term are showing as below:
LUX:CIPLA'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 8.71 Med: 15.78 Max: 24.09
Current: 17.87
During the past 13 years, the highest EV-to-EBITDA of Cipla was 24.09. The lowest was 8.71. And the median was 15.78.
LUX:CIPLA's EV-to-EBITDA is ranked worse than 64.29% of 742
companies
in the Drug Manufacturers industry
Industry Median: 12.93
vs LUX:CIPLA: 17.87
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2026-07-27), Cipla's stock price is $18.10.
Cipla's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 was $0.459. Therefore, Cipla's PE Ratio (TTM) for today is 39.43.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Cipla (LUX:CIPLA) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Cipla's share price for today is $18.10.
Cipla's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.459.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Cipla's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Cipla's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cipla EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cipla's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Cipla's EV-to-EBITDA falls into.
Cipla's current Enterprise Value is $13,656 Mil.
Cipla's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $643 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cipla (LUX:CIPLA) has a EV-to-EBITDA of 21.23 as of Jul. 27, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Cipla. This is 35% above median its historical median of 15.78. Over the past decade, Cipla's EV-to-EBITDA has ranged from 8.71 to 24.09. According to the industry distribution chart, Cipla ranks #477 out of 742 companies in the Drug Manufacturers industry, placing it in the top 64.3%.
Is Cipla's EV-to-EBITDA too high?
Cipla's current EV-to-EBITDA of 21.23 is 35% above median its 10-year median of 15.78. Over the past 10 years, this metric has ranged from a low of 8.71 to a high of 24.09. The Drug Manufacturers industry median EV-to-EBITDA is 12.93. Cipla's value of 21.23 is 64.2% above this industry median. Based on the distribution chart, Cipla ranks #477 out of 742 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Cipla has a GF Score™ of 97/100, reflecting its overall financial health beyond just this single metric.
How does Cipla's EV-to-EBITDA compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Cipla ranks #477 out of 742 companies for EV-to-EBITDA. This places Cipla in the lower half of its industry. The industry median EV-to-EBITDA is 12.93. Cipla's value of 21.23 is 64.2% above this benchmark. Historically, Cipla's own EV-to-EBITDA has ranged from 8.71 to 24.09 over the past decade. While the company's 10-year median is 15.78 vs. the industry median of 12.93, Cipla has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 12.93, based on 742 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cipla's current EV-to-EBITDA of 21.23 is 64.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Cipla. For the Drug Manufacturers industry, the median EV-to-EBITDA is 12.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cipla's current EV-to-EBITDA is 21.23, which is 35% above median its own 10-year median of 15.78. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cipla stock overvalued right now?
Cipla (LUX:CIPLA) has a current EV-to-EBITDA of 21.23. The stock's GF Value™ is $19.91, compared to a current price of $18.10 — trading 9.1% below its estimated fair value. The current EV-to-EBITDA is 21.23, which is 35% above median its 10-year median of 15.78 and 64.2% above the Drug Manufacturers industry median of 12.93. Cipla's overall GF Score™ is 97/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Cipla (LUX:CIPLA), the current EV-to-EBITDA is 21.23 as of Jul. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cipla (LUX:CIPLA) Overvalued in 2026?
Based on GuruFocus' analysis, Cipla stock appears to be undervalued.
The current stock price of $18.10 is trading 9.1% below its estimated GF Value™ of $19.91.
Key valuation signals for LUX:CIPLA:
EV-to-EBITDA: 21.23 (35% above median its 10-year median of 15.78)
GF Value™: $19.91 vs. price of $18.10 (9.1% below fair value)
Industry Position: 64.2% above the Drug Manufacturers median (#477 of 742)
No single metric tells the full story. See the LUX:CIPLA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cipla Ltd is a drug manufacturing company that focuses on a variety of pharmaceutical products. The company's product portfolio spans complex generics as well as drugs in the respiratory, anti-retroviral, urology, cardiology, anti-infective, CNS, and various other key therapeutic segments. The bulk of its sales are generated in India, although it maintains a large world-wide presence. Cipla's growth plan focuses on new product launches. It has two segments Pharmaceuticals and new ventures. It derives maximum revenue from Pharmaceuticals Segment.
97GF Score
Get the complete analysis for LUX:CIPLA
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LUX:CIPLA has been successfully added to your 
